Fly News Breaks for February 25, 2020
Feb 25, 2020 | 21:02 EDT
Piper Sandler analyst Joseph Catanzaro raised his price target on Iovance Biotherapeutics to $40 and kept his Outperform rating after its Q4 earnings beat and with the company announcing that its timelines for melanoma and cervical registrational cohort filings remaining unchanged by year-end FY20. The analyst also maintains his view of Iovance as the leader in solid tumor targeting cell therapy and contends that some of its rumored potential acquirers do as well.
News For IOVA From the Last 2 Days
There are no results for your query IOVA